Business context and reporting period
The filing is Proteon Therapeutics, Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2016. The request metadata names Protara Therapeutics, Inc.; the filing itself identifies the registrant as Proteon Therapeutics, Inc.
Proteon is a development-stage biopharmaceutical company with no product sales to date. Its lead candidate, vonapanitase, is being developed to improve arteriovenous fistula (AVF) patency in patients with chronic kidney disease undergoing hemodialysis.
Financial results and liquidity
Amounts below are in millions of dollars unless noted.
| Metric | Q2 2016 | Q2 2015 | Six months 2016 | Six months 2015 |
|---|---|---|---|---|
| Revenue from product sales | None to date | None to date | None to date | None to date |
| Research and development expense | $5.24 | $3.09 | $9.59 | $5.72 |
| General and administrative expense | $2.61 | $1.89 | $5.08 | $3.88 |
| Total operating expenses | $7.85 | $4.98 | $14.67 | $9.60 |
| Net loss | $7.91 | $5.07 | $14.46 | $9.65 |
| Net loss per share | $0.48 | $0.31 | $0.87 | $0.59 |
- For the six months ended June 30, 2016, operating cash use was $11.46 million; investing activities provided $5.49 million, largely reflecting investment maturities net of purchases; financing activities provided $0.14 million. Cash and cash equivalents fell by $5.85 million to $34.19 million.
- At June 30, 2016, cash, cash equivalents and available-for-sale investments totaled $53.67 million. Current liabilities were $4.74 million, stockholders’ equity was $50.93 million, and the balance sheet reported no debt.
- Management estimated available cash and investments would fund operations and capital expenditures into Q4 2017. The company cautioned that its existing resources were not expected to fund completion of PATENCY-2.
- No product revenue had been generated. The filing reports an accumulated deficit of $145.71 million and expects significant future losses.
Material changes versus the prior comparable period
- Six-month operating expenses increased $5.07 million and net loss increased $4.81 million year over year. R&D rose $3.87 million, mainly from manufacturing pre-validation and validation work, clinical-trial costs and personnel; G&A rose $1.21 million, primarily from personnel and overhead.
- Q2 net loss increased $2.83 million year over year. The filing attributes the higher R&D expense chiefly to manufacturing work and increased personnel costs.
- Six-month operating cash use increased from $8.47 million to $11.46 million. Cash and investments combined declined from $65.26 million at December 31, 2015 to $53.67 million at June 30, 2016.
- Other income/expense improved year over year for the six-month period, principally because of changes in the fair value of foreign-currency forwards and Swiss-franc-denominated balances.
Outlook, risks and unusual items
- PATENCY-1 completed enrollment in October 2015; top-line results were expected in December 2016. PATENCY-2 began enrollment in August 2015, with completion expected in Q1 2017.
- Management said it might discuss a BLA supported by PATENCY-1 with the FDA if results were compelling, but the FDA could require PATENCY-2 or additional studies. The company also expected to initiate two Phase 1 studies in peripheral artery disease in 2016, subject to its plans and resources.
- A key efficacy uncertainty is that the Phase 2 primary endpoint did not show statistically significant benefit for the 30-microgram dose versus placebo. The company’s more favorable radiocephalic-AVF subgroup analyses were not prespecified and may not be sufficient to support approval.
- Lonza manufacturing purchase obligations totaled CHF 9.8 million, all due within one year; approximately $1.3 million was reflected in accrued expenses. The company relied on third parties for manufacturing and clinical work, including Lonza for active pharmaceutical ingredient supply.
- Outstanding Swiss-franc forward contracts had a $0.24 million fair-value liability at quarter-end. Because hedge accounting was not applied, changes in contract value could create earnings volatility.
- Major risks include clinical-trial efficacy, enrollment and timing; regulatory approval; manufacturing and supplier dependence; foreign-exchange exposure; future financing needs and potential dilution. The $40 million at-the-market offering program was available, but no sales had begun by June 30, 2016.
- Management reported disclosure controls were effective at a reasonable-assurance level and no material change in internal control over financial reporting. The company reported no material legal proceeding and no material subsequent event affecting the statements.
Important facts for investors to verify
- Confirm the registrant identity: this filing is for Proteon Therapeutics, Inc., notwithstanding the Protara name in the request metadata.
- Check the actual PATENCY-1 results and subsequent regulatory discussions, including whether the Phase 2 endpoint and post-hoc subgroup findings were borne out.
- Assess PATENCY-2 enrollment, trial costs and the timing and amount of additional capital needed; the stated runway was an estimate, not a guarantee.
- Review progress, cost and timing of Lonza manufacturing and validation obligations, as well as any changes in Swiss-franc exposure.
- Verify any later use of the ATM program and the resulting financing terms and shareholder dilution.